Purification and characterization of an immunogenic outer membrane protein of Shigella flexneri 2a

Vaccine

Volumn 27, Issue 42, 2009, Pages 5855-5864

  Pore, Debasis ^a   Chowdhury, Pinki ^a   Mahata, Nibedita ^a   Pal, Amit ^a   Yamasaki, Shinji ^b   Mahalanabis, Dilip ^c   Chakrabarti, Manoj K ^a  

^a NATIONAL INSTITUTE OF CHOLERA AND ENTERIC DISEASES   (India)

^b Graduate School of Life and Environmental Sciences   (Japan)

^c SOCIETY FOR APPLIED STUDIES   (India)

Author keywords

Immunogen; Major outer membrane proteins; Shigellosis; Vaccine

Indexed keywords

EPITOPE; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 12P70; NITRIC OXIDE; OUTER MEMBRANE PROTEIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN GLYCOSYLATION; PROTEIN PURIFICATION; SHIGELLA FLEXNERI;

ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; CELLS, CULTURED; CROSS REACTIONS; GLYCOSYLATION; GRANULOCYTE COLONY-STIMULATING FACTOR; IMMUNE SERA; INTERLEUKIN-12; MACROPHAGES; MICE; MICE, INBRED BALB C; NITRIC OXIDE; SHIGELLA FLEXNERI;

EID: 69949107472     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.07.054     Document Type: Article

References (45)

1. Kotloff K.L., Winickoff J.P., Ivanoff B., Clemens J.D., Swedlow D.L., Sansonetti P.J., et al. Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull World Health Organ 77 (1999) 651-666
2. Parry J., Duggal H., Beaumont M., Jeckinson H., and Price C. A report of an outbreak of shigellosis in a primary school in Staffordshire. Pub Health 115 (2001) 295-300
3. Garcia-Fulgueiras A., Sanchez S., Guillen J.J., Marsillia B., Aladuena A., and Navarro C. A large outbreak of Shigella sonnei gastroenteritis associated with consumption of fresh pasteurized milk cheese. Eur J Epidemiol 17 (2001) 533-538
4. Diarrhoeal disease due to Shigella in vaccines. Immunization and biologicals. Website (http://www.who.int/vaccines/en/shigella.shtml) of World Health Organization updated on May 2002.
5. Ashkenazi S., Levy I., Kazaronovsky V., and Samra Z. Growing antimicrobial resistance of Shigella isolates. J Antimicrob Chemother 51 (2003) 427-429
6. Sarkar K., Ghosh S., Niyogi S.K., and Bhattacharya S.K. Shigella dysenteriae type 1 with reduced susceptibility to fluoroquinolones. Lancet 361 (2003) 785
7. Anders K., Li A., Zhao C.R., Karlsson K., Minh N.B., and Lindberg A.A. Safety and immunogenicity of the auxotrophic Shigella flexneri 2a vaccine SFL1070 with a deleted aroD gene in adult Swedish volunteers. Vaccine 13 (1995) 88-89
8. Coster T.S., Charles H.W., Lillian L., VanDeVerg A., Hartman A.B., Oaks E.V., et al. Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602. Infect Immun 67 (1999) 3437-3443
9. Katz D.E., Coster T.S., Wolf M.K., Trespalacios F.C., Cohen D., Robins G., et al. Two studies evaluating the safety and immunogenicity of a live, attenuated Shigella flexneri 2a vaccine (SC602) and excretion of vaccine organisms in North American volunteers. Infect Immun 72 (2004) 923-930
10. Kotloff K.L., Noriega F., Losonsky G.A., Sztein M.B., Wasserman S.S., Nataro J.P., et al. Safety, immunogenicity, and transmissibility in humans of cvd 1203, a live oral Shigella flexneri 2a vaccine candidate attenuated by deletions in aroA and virG. Infect Immun 64 (1996) 4542-4548
11. Noriega F.R., Losonsky G., Lauderbaugh C., Liao F.M., Wang J.Y., and Levine M.M. Engineered ΔguaB-A ΔvirG Shigella flexneri 2a strain CVD 1205: construction safety and immunogenicity, and potential efficacy as a mucosal vaccine. Infect Immun 64 (1996) 3055-3061
12. Passwell J.H., Harlev E., Ashkenazi S., Chu C., Miron D., Ramon R., et al. Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel. Infect Immun 69 (2001) 1351-1357
13. Ranallo R.T., Fonseka C.P., Cassels F., Srinivasan J., and Venkatesan M.M. Construction and characterization of bivalent Shigella flexneri 2a vaccine strains SC608 (pCFAI) and SC608 (pCFAI/LTB) that express antigens from enterotoxigenic Escherichia coli. Infect Immun 73 1 (2005) 258-267
14. Peng X., Ye X., and Wang S. Identification of novel immunogenic proteins of Shigella flexneri 2a by proteomic methodologies. Vaccine 22 (2004) 2750-2756
15. Ying T., Wang H., Li M., Wang J., Shi Z., Feng E., et al. Immunoproteomics of outer membrane proteins and extracellular proteins of Shigella flexneri 2a 2457T. Proteomics 5 (2005) 4777-4793
16. Jennison A.V., Raquib R., and Verma N.K. Immunoproteomic analysis of soluble and membrane proteins of Shigella flexneri 2a 2457T. World J Gastroenterol 12 41 (2006) 6683-6688
17. Mukhopadhaya A., Mahalanabis D., Khanam J., and Chakrabarti M.K. Protective efficacy of oral immunization with heat-killed Shigella flexneri 2a in animal model: study of cross protection, immune response and antigenic recognition. Vaccine 21 (2003) 3043-3050
18. Mukhopadhaya A., Mahalanabis D., and Chakrabarti M.K. Role of Shigella flexneri 2a 34 kDa outer membrane protein in induction of protective immune response. Vaccine 24 (2006) 6028-6036
19. Sereny B. Experimental keratoconjunctivitis shigellosa. Acta Microbial Acad Sci Hung 4 (1957) 367-376
20. Filip C., Fletcher G., Wullf J.L., and Earhart C.F. Solubilization of the cytoplasmic membrane Escherichia coli by the ionic detergent sodium lauryl sarcosinate. J Bacteriol 115 (1973) 717-722
21. Munson Jr. R.S., and Granoff D.M. Purification and partial characterization of outer membrane proteins P5 and P6 from Haemophilus influenzae type b. Infect Immun 49 (1985) 544-549
22. Murphy T.F., Bartos L.C., Campagnari A.A., Nelson M.B., and Apicella M.A. Antigenic characterization of the P6 protein of nontypable Haemophilus influenzae. Infect Immun 54 (1986) 774-779
23. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72 (1976) 248-254
24. Laemmli U.K. Change of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 (1970) 680-685
25. Matsudaira P. Sequence from picomole quantities of protein electroblotted onto polyvinylidene difluoride membranes. J Biol Chem 262 (1987) 10035-10038
26. Towbin H., Steeling T., and Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 76 (1979) 4350-4354
27. Rabbani G.H., Albert M.J., Rahman H., Kabir I., Alam K., and Ansaruzzaman M. Development of an improved animal model of shigellosis in the adult rabbit by colonic infection with Shigella flexneri 2a. Infect Immun 63 (1995) 4360-4367
28. Klauser T., Pohlner J., and Meyer T.F. Extracellular transport of cholera toxin B subunit using Neisseria IgA protease beta-domain: conformation-dependent outer membrane translocation. EMBO J 9 (1990) 1991-1999
29. Loeb M.R. Immunoblot method for identifying surface components, determining their cross-reactivity, and investigating cell topology: results with Haemophilus influenzae type b. Anal Biochem 143 (1984) 196-204
30. Le Maire M., Rivas E., and Moller J.V. Use of chromatography for determining of size and molecular weight of proteins; further caution. Anal Biochem 106 (1980) 12-21
31. Haselbeck A., and Hosel W. Immunological detection of glycoproteins on blots based on labeling with digoxigenin. Methods Mol Biol 14 (1993) 161-173
32. Ray A., Chatterjee N.S., Bhattacharya S.K., and Biswas T. Porin of Shigella dysenteria enhances mRNA levels for Toll-like receptor 2 and MyD88, up-regulate CD80 of murine macrophage, and induces the release of IL-12. FEMS Immunol 39 (2003) 213-219
33. Krakauer T., Vileck J., and Oppenheim J.J. In: Paul W.E. (Ed). Fundamental immunology (1999), Lippincott-Raven, Philadelphia 775-811
34. Eftink M.R. The use of fluorescence methods to monitor unfolding transitions in proteins. Biochemistry (Moscow) 63 (1988) 276-284
35. Olden K., Parent J.B., and White S.L. Carbohydrate moieties of glycoproteins. A re-evaluation of their function. Biochim Biophys Acta 650 (1982) 209-232
36. Nathan C., and Shiloh M.U. Reactive oxygen and nitrogen intermediates in the relationship between mammalian hosts and microbial pathogens. Proc Natl Acad Sci (USA) 97 (2000) 8841-8848
37. Orr N., Robin G., Cohen D., Arnon R., and Lowell G.H. Immunogenicity and efficacy of oral or intranasal Shigella flexneri 2a and Shigella sonnei proteosome-lipopolysaccharide vaccines in animal models. Infect Immun 61 6 (1993) 2390-2395
38. Loppnow H., Libby P., Freudenberg M., Krauss J.H., Weckesser J., and Mayer H. Cytokine induction by lipopolysaccharide (LPS) corresponds to lethal toxicity and is inhibited by nontoxic Rhodobacter capsulatus LPS. Infect Immun 58 11 (1990) 3743-3750
39. Clackson T., and Wells J.A. A hot spot of binding energy in a hormone receptor interface. Science 267 (1995) 383-386
40. Tagawa Y., Haritani M., Ishikawa H., and Yuasa N. Characterization of a heat-modifiable outer membrane protein of Haemophilus somnus. Infect Immun 61 5 (1993) 1750-1755
41. Hanisc F.G., and Ninkovic T. Immunology of O-glycosylated proteins: approaches to the design of a MUC1 glycopeptide-based tumor vaccine. Curr Protein Pept Sci 7 4 (2006) 307-315
42. Mosmann T.R., and Coffman R.L. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 7 (1989) 145-173
43. Hsieh C.S., Macatonia S.E., Tripp C.S., Wolf S.F., O'Garra A., and Murphy K.M. Development of TH1 CD4p T cells through IL-12 produced by Listeria-induced macrophages. Science 260 (1993) 547-549
44. Schmitt E., Hoehn P., Huels C., Goedert S., Palm N., Rüde E., et al. T helper type 1 development of naive CD4p T cells requires the coordinate action of interleukin-12 and interferon-gamma and is inhibited by transforming growth factor-beta. Eur J Immunol 24 (1994) 793-798
45. Roilides E., Walsh T.J., Pizzo P.A., and Rubin M. Granulocyte colony stimulating factor enhances the phagocytic and bactericidal activity of normal and defective human neutrophils. J Infect Dis 163 (1991) 579-583